IL13 and metabolic dysfunction-associated steatotic liver disease: Moreover, recent studies suggest that T helper 2 (Th2)–derived cytokines, particularly IL-4 and IL-13, may modulate hepatic RAS activity and contribute to the development of SAH in individuals with MASLD and obesity (8).